CN118251222A - 用tyk2抑制剂治疗脱发障碍的方法 - Google Patents

用tyk2抑制剂治疗脱发障碍的方法 Download PDF

Info

Publication number
CN118251222A
CN118251222A CN202280075809.3A CN202280075809A CN118251222A CN 118251222 A CN118251222 A CN 118251222A CN 202280075809 A CN202280075809 A CN 202280075809A CN 118251222 A CN118251222 A CN 118251222A
Authority
CN
China
Prior art keywords
treated
tyk2
hair follicles
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280075809.3A
Other languages
English (en)
Chinese (zh)
Inventor
I·M·卡特利特
J·金
M·贝托利尼
J·埃德尔坎普
T·罗伊尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to CN202411332236.5A priority Critical patent/CN119345364A/zh
Publication of CN118251222A publication Critical patent/CN118251222A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
CN202280075809.3A 2021-09-23 2022-09-22 用tyk2抑制剂治疗脱发障碍的方法 Pending CN118251222A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411332236.5A CN119345364A (zh) 2021-09-23 2022-09-22 用tyk2抑制剂治疗脱发障碍的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163247672P 2021-09-23 2021-09-23
US63/247,672 2021-09-23
PCT/US2022/044346 WO2023049241A1 (en) 2021-09-23 2022-09-22 Methods of treating hair-loss disorders with tyk2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411332236.5A Division CN119345364A (zh) 2021-09-23 2022-09-22 用tyk2抑制剂治疗脱发障碍的方法

Publications (1)

Publication Number Publication Date
CN118251222A true CN118251222A (zh) 2024-06-25

Family

ID=83899658

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280075809.3A Pending CN118251222A (zh) 2021-09-23 2022-09-22 用tyk2抑制剂治疗脱发障碍的方法
CN202411332236.5A Pending CN119345364A (zh) 2021-09-23 2022-09-22 用tyk2抑制剂治疗脱发障碍的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411332236.5A Pending CN119345364A (zh) 2021-09-23 2022-09-22 用tyk2抑制剂治疗脱发障碍的方法

Country Status (10)

Country Link
US (1) US20240390372A1 (https=)
EP (1) EP4404930A1 (https=)
JP (1) JP2024533700A (https=)
KR (1) KR20240065283A (https=)
CN (2) CN118251222A (https=)
AU (1) AU2022350509A1 (https=)
CA (1) CA3232812A1 (https=)
IL (1) IL311624A (https=)
MX (1) MX2024003510A (https=)
WO (1) WO2023049241A1 (https=)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
TWI582077B (zh) * 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
TW202515876A (zh) * 2017-03-08 2025-04-16 日商武田藥品工業股份有限公司 Tyk2抑制劑及其用途
JP7113023B2 (ja) * 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
KR102848769B1 (ko) 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
US20230093099A1 (en) * 2019-04-02 2023-03-23 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
US11357775B2 (en) * 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
SG11202112043PA (en) * 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
US12570637B2 (en) 2019-06-12 2026-03-10 Bristol-Myers Squibb Company Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
JP7812785B2 (ja) 2019-09-18 2026-02-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の剤形
AU2021205465A1 (en) * 2020-01-06 2022-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN111704617B (zh) * 2020-06-15 2022-08-23 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN112142675B (zh) * 2020-10-09 2021-11-30 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途

Also Published As

Publication number Publication date
KR20240065283A (ko) 2024-05-14
CA3232812A1 (en) 2023-03-30
JP2024533700A (ja) 2024-09-12
IL311624A (en) 2024-05-01
EP4404930A1 (en) 2024-07-31
US20240390372A1 (en) 2024-11-28
AU2022350509A1 (en) 2024-04-04
MX2024003510A (es) 2024-04-09
WO2023049241A1 (en) 2023-03-30
CN119345364A (zh) 2025-01-24

Similar Documents

Publication Publication Date Title
Ruess et al. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Zhuang et al. Induction of M2 macrophages prevents bone loss in murine periodontitis models
Svensson et al. Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal
Altshuler-Keylin et al. Beige adipocyte maintenance is regulated by autophagy-induced mitochondrial clearance
Zhang et al. Growth hormone-releasing hormone receptor antagonist modulates lung inflammation and fibrosis due to bleomycin
Yu et al. Targeting glutamine metabolism ameliorates autoimmune hepatitis via inhibiting T cell activation and differentiation
Swamynathan et al. Klf4 regulates the expression of Slurp1, which functions as an immunomodulatory peptide in the mouse cornea
Lin et al. Heme oxygenase‐1 directly binds STAT 3 to control the generation of pathogenic Th17 cells during neutrophilic airway inflammation
Lyu et al. Expression of HIF1α in intestinal epithelium restricts arthritis inflammation by inhibiting RIPK3-induced cell death machinery
Shibata et al. Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy
Huang et al. M2‐like macrophages polarized by Foxp3− Treg‐of‐B cells ameliorate imiquimod‐induced psoriasis
Katoh Emerging treatments for atopic dermatitis
Shen et al. Melatonin attenuates imiquimod-induced psoriasis-like inflammation and restores the th17/treg immune balance
Lai et al. Novel approach to alleviate lupus nephritis: targeting the NLRP3 inflammasome in CD8+ CD69+ CD103+ TRM cells
Faust et al. Adipocyte associated glucocorticoid signaling regulates normal fibroblast function which is lost in inflammatory arthritis
Wei et al. JAK2/STAT5 inhibition protects mice from experimental autoimmune encephalomyelitis by modulating T cell polarization
Zou et al. Fluvoxamine inhibits Th1 and Th17 polarization and function by repressing glycolysis to attenuate autoimmune progression in type 1 diabetes
EP3752134B1 (en) Methods and compositions for treating vitiligo
Zhang et al. CCN1 upregulates IL‐36 via AKT/NF‐κB and ERK/CEBP β‐mediated signaling pathways in psoriasis‐like models
US20240390372A1 (en) Methods of treating hair-loss disorders with tyk2 inhibitors
Karaś et al. The cyclin‐dependent kinase inhibitor AT7519 is a human RORγt agonist
Liu et al. Exogenous ephrin-A3 reverses loss of vaginal epithelial barrier protection in progestin-treated mice
Gimenez-Arnau et al. Urticaria Beyond Omalizumab: What is Next?
Buckley et al. Early-life thymectomy results in visceral adipose tissue inflammation and glucose intolerance
EP4213813A1 (en) Dosage forms for tyk2 inhibitors comprising swellable cores

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination